 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- || JNJ-55920839 / J&J
Clinical, Journal: Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition. (Pubmed Central) - Oct 8, 2021
These signatures may enable enrichment for treatment responders when using IFN-I-suppressing treatments in SLE.
- || JNJ-55920839 / J&J
Clinical, PK/PD data, Journal: Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. (Pubmed Central) - Jan 27, 2021
P1
Pharmacokinetic and pharmacodynamic analyses of the data from this study demonstrated that there was biphasic disposition in both healthy subjects and subjects with SLE, CL was faster in subjects with SLE, and increases in total IFNα/ω levels were observed in both healthy subjects and subjects with SLE after treatment with JNJ-55920839, thus further development is supported. The study is registered at ClinicalTrials.gov NCT02609789.
- | JNJ-55920839 / J&J
Trial completion: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 10, 2018
P1, N=76, Completed, Sponsor: Janssen Research & Development, LLC
The study is registered at ClinicalTrials.gov NCT02609789. Active, not recruiting --> Completed
- | JNJ-55920839 / J&J
Enrollment closed: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 21, 2018
P1, N=80, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| JNJ-55920839 / J&J
Enrollment open, Trial primary completion date: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 12, 2017
P1, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Suspended --> Recruiting | Trial primary completion date: Dec 2017 --> Sep 2018
- | JNJ-55920839 / J&J
Trial suspension: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 2, 2017
P1, N=80, Suspended, Sponsor: Janssen Research & Development, LLC
Suspended --> Recruiting | Trial primary completion date: Dec 2017 --> Sep 2018 Recruiting --> Suspended
- ||| JNJ-55920839 / J&J
Enrollment open: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 11, 2016
P1, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ||| JNJ-55920839 / J&J
New P1 trial: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 21, 2015
P1, N=80, Not yet recruiting, Sponsor: Janssen Research & Development, LLC